✦ LIBER ✦

Clinical development plan: DHEA analog 8354

✍ Scribed by NCI, DCPC Chemoprevention Branch and Agent Development Committee

Publisher: John Wiley and Sons
Year: 1994
Tongue: English
Weight: 500 KB
Volume: 56
Category: Article
ISSN: 0730-2312
DOI: 10.1002/jcb.240560911

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical development plan: Aspirin

✍ NCI, DCPC Chemoprevention Branch and Agent Development Committee 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 915 KB

Clinical development plan: Ibuprofen

✍ NCI, DCPC Chemoprevention Branch and Agent Development Committee 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 570 KB

## IBUPROFEN DRUG IDENTIFICATION CAS Registry No.: 15687-27-1 CAS Name (9CI): a-Methyl-4-(2-methylpropyl)benzeneacetic Acid Synonyms: Advil@ (Active Ingredient) Brufen 2-(4-Isobutylphenyl)propionic Acid Midol 1200@ (Active Ingredient) Motrin@ (Active Ingredient) Nuprin@ (Active Ingredient

Clinical development plan: Oltipraz

✍ NCI, DCPC Chemoprevention Branch and Agent Development Committee 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 1000 KB

Clinical development plan: Piroxicam

✍ NCI, DCPC Chemoprevention Branch and Agent Development Committee 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 926 KB

Clinical development plan: Sulindac

✍ NCI, DCPC Chemoprevention Branch and Agent Development Committee 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 1010 KB

was discovered in a search for a less toxic version of indomethacin, a structurally related compound. Sulindac is indicated for acute and long-term treatment of the symptoms of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, shoulder bursitis/ tendinitis, and acute gouty arthritis at d

Clinical development plan: (+)-Vorozole

📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 748 KB